A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO - 204)

Trial Profile

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO - 204)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Epacadostat (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer; Diffuse large B cell lymphoma; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO-204
  • Sponsors Bristol-Myers Squibb; Incyte Corporation
  • Most Recent Events

    • 06 Jun 2017 Preliminary results (n=241;data cut off: 29 Oct 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Efficacy data in patients with squamous cell carcinoma of the head and neck (SCCHN), treatment-naive advanced melanoma (MEL), ovarian cancer (OC), and colorectal cancer (CRC) were presented at the American Society of Clinical Oncology (ASCO) annual meeting, according to an Incyte Corporation media release
    • 05 Jun 2017 Efficacy data in patients with squamous cell carcinoma of the head and neck (SCCHN), treatment-naive advanced melanoma (MEL), ovarian cancer (OC), and colorectal cancer (CRC) published in an Incyte Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top